Pepscan Appoints new Chief Business Officer
LELYSTAD,
Therapeutics, the Dutch biotech company focusing on protein mimicry for the
discovery of therapeutics peptides and antibodies, announced today the
appointment of
Pepscan from Octoplus, where he held the position of Senior Manager Business
Development, responsible for licensing, partnering, and alliance management
activities.
“We are delighted to bring
enormous potential of Pepscan’s pioneering CLIPS platform for the discovery
and development of therapeutic peptides and antibodies,” said Wim Mol, CEO of
Pepscan. “Pepscan has recently established a number of research collaboration
and licensing agreements with major pharma and biotech companies, and
Michiel’s business savvy and deal-making experience make him ideal to further
expand our partnership base.”
“I’m very excited to join the company at this pivotal stage,” stated
Lodder. “The potential of the CLIPS technology to significantly improve
therapeutic peptide leads or generate antibodies against intractable targets
such as GPCR’s and ion channels is far-reaching. Through successful
partnering Pepscan can play an important role in the advancement of
innovative peptide and antibody therapeutics.”
Leiden, and a PhD in Bio-Organic Chemistry from the
he contributed or delivered numerous strategic partnerships and license deals
encompassing technology platform and product deals. In his role as Director
Business Development,
and management of OctoPlus Inc., located in
About Pepscan
Pepscan is a privately held company based in Lelystad,
Pepscan is using its proprietary high throughput CLIPS protein mimicking
technology for the development of novel constrained therapeutic peptides and
immunogens. Besides its pipeline of proprietary anti- GPCR monoclonal
antibody products Pepscan has various ongoing collaborations with leading
pharmaceutical and biotech companies to develop novel therapeutics based on
the proprietary CLIPS technology.
About CLIPS technology
CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to
present one or more peptides in a structurally constrained configuration.
These molecules behave as functional mimics of complex protein domains. CLIPS
peptides have been used in antibody and vaccine programs to create superior
immunogens in the generation of antibodies against disease relevant protein
targets. This is especially valuable in the case of proteins that are
inaccessible as recombinant proteins, such as GPCRs.
SOURCE Pepscan Therapeutics BV
